(Reuters) - A panel of expert advisers to the U.S. Food and Drug Administration (FDA) on Friday voted in favor of authorizing Johnson & Johnson (NYSE:JNJ)'s COVID-19 vaccine for emergency use, bringing it an important step closer to a U.S. rollout.
The FDA is likely to authorize the one-shot vaccine within a day or so after receiving the recommendation of the panel, making it the third available in the United States.